LP-184

FDA grants Fast Track Designation to LP-184 for Triple Negative Breast Cancer (TNBC), recognizing its potential to address unmet needs in aggressive cancers. LP-184 has shown significant preclinical efficacy in TNBC models, including those resistant to PARP inhibitors, and promising synergy with checkpoint inhibitors. The drug is currently in a Phase 1A clinical trial for multiple solid tumor indications.

Lantern Pharma's LP-184 receives FDA Fast Track Designation for Triple Negative Breast Cancer, following a previous designation for Glioblastoma. LP-184, developed using the RADR® AI platform, demonstrated tumor regression in TNBC models and is in Phase 1A trials for safety and tolerability in solid tumors. The drug targets TNBC, which has limited treatment options and poor prognosis.

Lantern Pharma's LP-184 receives second FDA Fast Track Designation for TNBC, following earlier designation for Glioblastoma. LP-184, developed with AI platform RADR®, shows tumor regression in TNBC models and is in Phase 1A trial for solid tumors.

Lantern Pharma shares rose 6% to $3.34 after FDA granted fast-track designation for LP-184 in triple negative breast cancer. This is the second fast-track designation for LP-184 in 2024, following glioblastoma in October. LP-184 is currently in a Phase 1A trial for safety and tolerability in solid tumors.

Lantern Pharma, Inc (NASDAQ:LTRN) reported 3Q:24 financial results with no revenues, $5.2 million in operating expenses, and a net loss of $4.5 million. The company gained rare pediatric disease designations for LP-184 and Fast Track designation for glioblastoma, and anticipates sufficient cash to support operations until late 2025.

Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer, effectiveness of chemotherapy in elderly patients with metastatic bladder cancer, treatment patterns and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients, enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer, nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma, biomarker-oriented therapy in bladder and renal cancer, predictive and prognostic biomarkers for targeted therapy in metastatic urothelial cancer, identification of a synthetic lethal relationship between nucleotide excision repair deficiency and irofulven sensitivity in urothelial cancer, anti-tumour compounds inducing DNA lesions exclusively processed by transcription- and replication-coupled repair pathways, cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells, targeting germline- and tumor-associated nucleotide excision repair defects in cancer, somatic ERCC2 mutations correlating with cisplatin sensitivity in muscle-invasive bladder cancer, comprehensive molecular characterization of muscle-invasive bladder cancer, and clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma.

Lantern Pharma reported Q3 2024 financial results and clinical updates, including an 86% clinical benefit rate in the LP-300 Harmonic™ Trial's initial cohort, expansion to Japan and Taiwan, and ongoing Phase 1 trials for LP-184 and LP-284 with no dose-limiting toxicities. LP-184 received FDA Fast Track Designation for Glioblastoma. Financial highlights include $28.1 million in cash and equivalents, R&D expenses of $3.7 million, and a net loss of $4.5 million ($0.42 per share). The company maintains three active clinical trials and advances AI-guided precision-oncology drug candidates.

Texas’s top hospitals recognized in 2025 America’s Best-in-State Hospitals ranking by Newsweek and Statista, with Houston Methodist Hospital leading. TCU and UT Arlington launch joint M.D.-Ph.D. program in biomedical engineering. UT Arlington’s North Texas Genome Center acquires $1 million next-generation genetic sequencer. Lantern Pharma’s LP-184 receives FDA Fast Track designation for treating glioblastoma.